Acumen Pharmaceuticals Inc (NAS:ABOS)
$ 3.8 0.11 (2.98%) Market Cap: 228.30 Mil Enterprise Value: 6.66 Mil PE Ratio: 0 PB Ratio: 0.80 GF Score: 20/100

Acumen Pharmaceuticals Inc at UBS BioPharma Conference Transcript

Nov 09, 2023 / 03:00PM GMT
Release Date Price: $1.86 (-8.82%)
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst

Good morning, and welcome to the UBS Biopharma Conference. I'm Colin Bristow, one of the biotech analysts. My pleasure to have Acumen Pharmaceuticals with us here today. On behalf of the company, we have Dan O'Connell, President and CEO. Dan, thanks for being with us today.

Daniel J. O;Connell
Acumen Pharmaceuticals, Inc. - CEO, President & Director

' -

Thanks, Colin.

Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst

So it's great to have you here sort of right after CTAD and some really interesting developments in the overall Alzheimer's space. Obviously, you guys had a presence at CTAD, some interesting updates. Before we sort of dig into 193, just what were some of the sort of most interesting takeaways for the field that you walked away with?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot